Drug Index

Mechanism :

Prazosin causes a decrease in total peripheral resistance. Studies suggest that the vasodilator effect of prazosin is related to selective blockade of post-synaptic alpha1-adrenoceptors. In patients with hypertension there is little change in cardiac output. In addition, clinical pharmacology studies have shown that prazosin antagonizes the vasopressor effect of i.v. phenylephrine, an alpha1-agonist.


Indication :

  • Hypertension

Contraindications :

Hypersensitivity to prazosin or related quinazolines. Not recommended for congestive heart failure due to mechanical obstruction. When giving first dose monitor for excessive hypotension or give at bedtime.


Dosing :

Initially 0.05-0.1 mg/kg/day orally in divided 8 hourly doses; titrate to 0.5 mg/kg/day.
Maximum dose: 20 mg/day.

Adverse Effect :

Vomiting, diarrhea, constipation, abdominal discomfort and/or pain, syncope, orthostatic hypotension, edema, dyspnea, tachycardia, faintness, nervousness, vertigo, depression, paresthesia, hallucinations, rash, pruritus, alopecia, lichen planus, urinary frequency, incontinence, impotence, priapism, blurred vision, reddened sclera, epistaxis, tinnitus, nasal congestion, liver function abnormalities, pancreatitis, decreased hematocrit/hemoglobin, diaphoresis, fever, arthralgia, positive ANA titre.


Interaction :

Prazosin has been administered without any adverse drug interaction in limited clinical experience to date with the following: cardiac glycosides - digitalis and digoxin; hypoglycemics - insulin, chlorpropamide, tolazamide and tolbutamide; tranquilizers and sedatives - chlordiazepoxide, diazepam and phenobarbital; antigout - allopurinol, colchicine and probenecid; antiarrhythmics - procainamide, propranolol and quinidine; and analgesics, antipyretics and anti-inflammatories - propoxyphene, ASA, indomethacin and phenylbutazone.
Diuretic or other Antihypertensive Agent: Addition of a diuretic or other antihypertensive agent to prazosin has been shown to cause an additive hypotensive effect.



Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in normal renal function
HDNot dialysed. Dose as in normal renal function
HDF/High fluxUnknown dialysability. Dose as in normal renal function
CAV/VVHDNot dialysed. Dose as in normal renal function

Hepatic Dose :

Drug is extensively metabolized in the liver, therefore initiation with lower dose is reasonable. Titration of dose should be done while monitoring clinical response.
09/28/2020 08:11:17 Prazosin
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0